We are live on ! Find out more

ORKA

Oruka Therapeutics

ORKA

Market cap $6.78B

102.42 USD

-5.54

5.13%

At close Updated Aug 24, 4:00 PM EDT

Pre-market

After hours

103.01

+0.59

0.58%

1 day

-5.13%

5 days

-7.12%

1 month

11.13%

3 months

73.42%

6 months

188.02%

Year to date

262.29%

1 year

605.86%

5 years

179.84%

10 years

-83.65%

About: Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Employees: 68

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.9%

Neutral 57.1%

Negative 0%

Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026.

Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

Zacks Investment Research

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program for ORKA-001 expected to begin in 1H 2027 ORCA-SURGE Week 16 data accelerated, now expected in 1Q 2027 ORCA-SPLASH, a Phase 2 trial of ORKA-002 in moderate-to-severe hidradenitis suppurativa, initiated ORKA-004, a novel half-life extended monoclonal antibody targeting TL1A, to enter the clinic in 4Q 2026 Cash, cash equivalents and marketable securities of $1.1 billion expected to fund the Company through a BLA filing for ORKA-001

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

The Motley Fool

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's direct holdings, reducing direct ownership from 26,696 to 16,406 shares.

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

Zacks Investment Research

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026.

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximately $700.4 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. In addition, Oruka has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,449,000 shares of Oruka's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are to be sold by Oruka. The offering is expected to close on or about April 30, 2026, subject to the satisfaction of customary closing conditions.

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

See News Rankings

Price charts implemented using Lightweight Charts™